Codiak, Aspiring to Make Exosome Drugs for Cancer, Nabs $76M to March Into Clinic

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Codiak Scales Up Exosome Capabilities, Snags $72.5M from Sarepta
Building On Our Immunology Understanding, Seeing Reasons for Hope